Protein Drugs Market: Global Industry Analysis and Forecast (2022-2029)

Protein Drugs Market size was valued at US$ 244.96 Bn. in 2021 and the total Protein Drugs revenue is expected to grow at 8.25% through 2022 to 2029, reaching nearly US$ 461.86 Bn.

Protein Drugs Market Overview:

Protein therapies, which were once a small subgroup of medical interventions, have expanded drastically in quantity and frequency of usage since the release of the first synthetic protein therapeutic i.e. human insulin. Protein therapies are already playing an important role in practically every sector of medicine, yet they are still in their infancy. Global Protein Drugs Market To know about the Research Methodology :- Request Free Sample Report Protein-based treatments are proving to be very effective in clinical trials, and their promise is being recognized at an unprecedented scale. More than 100 authentic and comparable recombinant protein therapeutics are available for clinical use in the European Union and the United States, with total sales of US$ 30 billion in 2021; monoclonal antibodies accounted for over 10 percent of total sales. Newly designed proteins are constantly being developed, including biospecific medicines and multispecific fusion proteins, monoclonal antibodies coupled with small molecule medicines, and proteins with enhanced pharmacokinetics. However, there have been no theoretically novel procedural advancements in the recent few decades equivalent, for example, to gene editing leading to the production of innovative therapeutic proteins. To overcome fundamental hurdles such as tolerance to therapy, accessibility to targets, the intricacy of biomolecules, and individual variances, it seems that a paradigm shift in approaches and knowledge of processes is required. In this report, the Protein Drugs market's growth reasons, as well as the market's many segments (Product, Application, Function, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Protein Drugs market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Protein Drugs market situation.

Protein Drugs Market Dynamics:

• One of the major drivers of the market is growing government financing and research and development spending in pharmaceutical and biotechnology firms. The R&D business has traditionally been investment-intensive due to substantial investigations and licensing procedures. Technology investments are at the top of the worldwide spending list. Governments see Investments in research and development as an essential component of a country's growth, global competitiveness, and public welfare. As a result, R&D spending and financing have steadily increased throughout the years. The global life science research and innovation spending is expected to increase by 4.1 percent to USD 2.7 trillion by 2021, as per the 2021 Global Research and innovation Funding Forecast. While the industry is the primary source of research and innovation financing, academia is equally important since research articles are written by academics. • A major restraint of the market is that the cost of recombinant proteins is decreasing. Whenever a growing number of firms enter a narrow market and provide comparable items with little uniqueness, price erosion occurs. In this situation, the price of such items has been found to consistently fall, slowing market growth. Progress in the field of recombinant protein manufacturing has reversed the previous trend, increasing output while decreasing cost, allowing such proteins to be produced on an industrial scale, and opening the door to the treatment of a wide range of illnesses and disorders. • COVID-19 impact on the protein drugs market. Because of efforts to understand the dynamics of the illness, the COVID-19 pandemic has stimulated scientific activities. We anticipate that the majority of recombinant protein production, as well as customized medicine, will expand at a consistent rate over the next six years. Because of the increased research effort, both the accessibility of research funds and the need for the manufacture of recombinant proteins (particularly immune reaction proteins relevant to COVID-19) are likely to boost. The COVID-19 has had a substantial influence on the life science sector. Companies that sell COVID-19-specific solutions have benefited. However, due to facility closures and the cessation of clinical investigations, there was a significant disruption in Research and development efforts. As a result, demand for commodities other than those connected to coronavirus has decreased.

Protein Drugs Market Segment Analysis:

By Product, the insulin segment is expected to grow at the fastest CAGR of 3.3% in the aforementioned forecast period. Diabetes is widely seen as a habits-related illness. With the growth in population throughout the world, the condition's prevalence has risen dramatically over time. Approximately 110 million individuals worldwide use insulin, including all patients with Type 1 diabetes and 10-20 percent of individuals with Type 2 diabetes. Even though insulin has been used to control diabetes for over 90 years, more than half of individuals who require it today cannot purchase or obtain it. Insulin treatment, which maintains blood sugar levels combined with insulin, nutrition, and lifestyle, is required for patients with Type 1 diabetes to avoid complications. Global Protein Drugs Market North America, particularly the United States, dominates the worldwide human insulin sector, mainly due to the country's high incidence of diabetes as a result of lifestyle choices. The cost aspect is a key problem in the United States since the country generates over half of the insulin income for the makers. The United States is the world's largest seller of long-acting insulin, Lantus. The bulk of diabetic medicine manufacturers sees the region as a vital market for increasing overall worldwide sales. Lantus is the most commonly used basal insulin in the world, with the largest chunk of the market in the United States.

Protein Drugs Market Regional Insights:

Due to the continent's diverse healthcare markets, the increased prevalence of acute and chronic medical disorders, and large Research and development proposals to create innovative metagenomic and genomic methods, the Asia Pacific is expected to offer significant growth opportunities to market players in the forecast period. Furthermore, the region's aging population, growing income levels, advances in medical infrastructure, rising healthcare spending, and the reduced manufacturing advantage given by growing Asian nations are projected to entice market participants to invest. The region's regulatory laws are also more adaptable and corporate-friendly, which attracts the interest of multinational firms that are already experiencing increased competition in established markets. The objective of the report is to present a comprehensive analysis of the Protein Drugs market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Protein Drugs market dynamics, structure by analyzing the market segments and projecting the Protein Drugs market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Protein Drugs market make the report investor’s guide.

Protein Drugs Market Scope: Inquire before buying

Global Protein Drugs Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US $ 244.96 Bn.
Forecast Period 2022 to 2029 CAGR: 8.25% Market Size in 2029: US $ 461.86 Bn.
Segments Covered: by Product • Monoclonal Antibodies • Insulin • Fusion Protein • Erythropoietin • Interferon
by Application • Metabolic Disorders • Immunologic Disorders • Hematological Disorders • Cancer • Genetic Disorders • Hormonal Disorders
by Function • Enzymatic and Regulatory Activity • Special Targeting Activity • Vaccines • Protein Diagnostics

Protein Drugs Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Protein Drugs Market Key Players

Abbott Laboratories • AstraZeneca • Amgen Inc • Baxter International Inc • Eli Lilly and Company • F.Hoffmann-La Roche Ltd • Johnson & Johnson • Merck & Co, Inc • Novo Nordisk A/S • Pfizer Inc • Sanofi • UCB Group • Genentech Inc • Teva Pharmaceuticals • Biogen Inc • Novartis • Generex Biotechnology FAQs: 1. Which is the potential market for Protein Drugs in terms of the region? Ans. The Asia Pacific is expected to offer significant growth opportunities to market players in the forecast period. 2. What are the restraints for new market entrants? Ans. A major restraint of the market is that the cost of recombinant proteins is decreasing. 3. What is expected to drive the growth of the Protein Drugs market in the forecast period? Ans. One of the major drivers of the market is growing government financing and research and development spending in pharmaceutical and biotechnology firms. 4. What is the projected market size & growth rate of the Protein Drugs Market? Ans. Protein Drugs Market size was valued at US$ 244.96 Bn. in 2021 and the total Protein Drugs revenue is expected to grow at 8.25% through 2022 to 2029, reaching nearly US$ 461.86 Bn. 5. What segments are covered in the Protein Drugs Market report? Ans. The segments covered are Product, Application, Function, and Region.
1. Global Protein Drugs Market: Research Methodology 2. Global Protein Drugs Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Protein Drugs Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Protein Drugs Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Protein Drugs Market Segmentation 4.1 Global Protein Drugs Market, by Product (2021-2029) • Monoclonal Antibodies • Insulin • Fusion Protein • Erythropoietin • Interferon 4.2 Global Protein Drugs Market, by Application (2021-2029) • Metabolic Disorders • Immunologic Disorders • Hematological Disorders • Cancer • Genetic Disorders • Hormonal Disorders 4.3 Global Protein Drugs Market, by Function (2021-2029) • Enzymatic and Regulatory Activity • Special Targeting Activity • Vaccines • Protein Diagnostics 5. North America Protein Drugs Market(2021-2029) 5.1 Global Protein Drugs Market, by Product (2021-2029) • Monoclonal Antibodies • Insulin • Fusion Protein • Erythropoietin • Interferon 5.2 Global Protein Drugs Market, by Application (2021-2029) • Metabolic Disorders • Immunologic Disorders • Hematological Disorders • Cancer • Genetic Disorders • Hormonal Disorders 5.3 Global Protein Drugs Market, by Function (2021-2029) • Enzymatic and Regulatory Activity • Special Targeting Activity • Vaccines • Protein Diagnostics 5.4 North America Protein Drugs Market, by Country (2021-2029) • United States • Canada • Mexico 6. Europe Protein Drugs Market (2021-2029) 6.1. European Protein Drugs Market, by Product (2021-2029) 6.2. European Protein Drugs Market, by Application (2021-2029) 6.3. European Protein Drugs Market, by Function (2021-2029) 6.4. European Protein Drugs Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Protein Drugs Market (2021-2029) 7.1. Asia Pacific Protein Drugs Market, by Product (2021-2029) 7.2. Asia Pacific Protein Drugs Market, by Application (2021-2029) 7.3. Asia Pacific Protein Drugs Market, by Function (2021-2029) 7.4. Asia Pacific Protein Drugs Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Protein Drugs Market (2021-2029) 8.1 Middle East and Africa Protein Drugs Market, by Product (2021-2029) 8.2. Middle East and Africa Protein Drugs Market, by Application (2021-2029) 8.3. Middle East and Africa Protein Drugs Market, by Function (2021-2029) 8.4. Middle East and Africa Protein Drugs Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Protein Drugs Market (2021-2029) 9.1. South America Protein Drugs Market, by Product (2021-2029) 9.2. South America Protein Drugs Market, by Application (2021-2029) 9.3. South America Protein Drugs Market, by Function (2021-2029) 9.4 South America Protein Drugs Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Abbott Laboratories 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 AstraZeneca 10.3 Amgen Inc 10.4 Baxter International Inc 10.5 Eli Lilly and Company 10.6 F.Hoffmann-La Roche Ltd 10.7 Johnson & Johnson 10.8 Merck & Co, Inc 10.9 Novo Nordisk A/S 10.10 Pfizer Inc 10.11 Sanofi 10.12 UCB Group 10.13 Genentech Inc 10.14 Teva Pharmaceuticals 10.15 Biogen Inc 10.16 Novartis 10.17 Generex Biotechnology

About This Report

Report ID 82226
Category Healthcare
Published Date February 2021
Updated Date Aug 2022
Contact Us